ADAM Trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in Merkel cell carcinoma patients with lymph node metastases; NCT03271372 Meeting Abstract
| Authors: | Chen, W.; Bhatia, S.; Brohl, A. S.; Chandra, S.; Dakhil, S.; Fecher, L. A.; Gao, L.; Gooley, T. A.; Hanna, G. J.; Hibbert, R.; Kelly, C.; Kiriluk, S.; Lewis, K.; Moschos, S.; Nghiem, P.; Thompson, J. A.; Tykodi, S. S. |
| Abstract Title: | ADAM Trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in Merkel cell carcinoma patients with lymph node metastases; NCT03271372 |
| Meeting Title: | 2nd International Merkel Cell Carcinoma Symposium |
| Journal Title: | Journal of Investigative Dermatology |
| Volume: | 142 |
| Issue: | 10 |
| Meeting Dates: | 2022 Apr 25-26 |
| Meeting Location: | Seattle, WA |
| ISSN: | 0022-202X |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | 2837 |
| Language: | English |
| ACCESSION: | WOS:000888821100014 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jid.2022.08.007 |
| Notes: | Meeting Abstract -- Source: Wos |
